KLAS Single Sign-On Performance Report Names Imprivata’s OneSign® Solution #1

Company Rates Highest Customer Scores for Clinician Satisfaction, Productivity and Workflow Enablement.

LEXINGTON, Mass. — December 21, 2010—Imprivata, the #1 independent single sign-on and access management provider for health care and other regulated industries, today announced that KLAS, the health care industry’s leading independent research firm, has named Imprivata’s OneSign® the number one Single Sign-On (SSO) product in its “2010 Single Sign-On: To Identity Management and Beyond” report.

“Imprivata led the pack as the highest-rated vendor in this report, excelling in keeping promises, ease of use, and delivering a product that works as promoted,” commented Paul Pitcher, author of the report and research director at KLAS. “Imprivata received more positive commentary on the solution’s ability to improve clinician satisfaction and employee productivity than any other vendor in this report. “

Imprivata’s emergence as the market leader in the KLAS Single Sign-On report comes on the heels of the company’s “Strong Positive” rating in the Gartner 2010 Marketscope for Enterprise Single Sign-On and further validates the value that Imprivata OneSign brings to healthcare organizations today. The company has seen unprecedented growth as hospitals and clinics turn to SSO and Strong Authentication to accelerate adoption of clinical applications to meet the government’s requirements for Meaningful Use of electronic medical records (EMR). Today more than one million care givers rely on Imprivata OneSign for fast and secure access to EMR and other healthcare applications.

“It is a very exciting time to be in the healthcare IT industry,” commented Ed Gaudet, Chief Marketing Officer at Imprivata. “The KLAS SSO report substantiates the elevated interest in Single Sign-on and Strong Authentication as a key component in accessing EMRs. From what we’re hearing from our customers, every hospital will require single sign-on to achieve meaningful use and CPOE requirements. ”

The Single Sign On: To Identity Management and Beyond report is available for purchase from KLAS: http://www.klasresearch.com/Store/ReportDetail.aspx?ProductID=603

About KLAS:
KLAS is a research firm specializing in monitoring and reporting the performance of health care vendors. KLAS' mission is to improve delivery, by independently measuring vendor performance for the benefit of our health care provider partners, consultants, investors, and vendors. Working together with executives from over 4500 hospitals and over 2500 clinics, KLAS delivers timely reports, trends, and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, and medical equipment vendors. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-800-920- 4109 to speak with a KLAS representative.

About Imprivata:
With more than one million health care users, Imprivata is the #1 independent provider of authentication and access management solutions for health care, transforming the way hospitals are transitioning from paper to digital. Focused on simplifying and securing access to electronic patient health information, Imprivata is enabling hospitals to create a secure environment that both streamlines clinical workflow and protects patient privacy. The Company’s signature OneSign® technology integrates within the daily clinical workflow, giving clinicians quick and convenient access to the critical patient information they need to deliver the highest level of quality health care. For more information, please visit www.imprivata.com or follow us on Twitter at @Imprivata.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

# # #

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

Follow Imprivata on Twitter: https://twitter.com/Imprivata